http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021081204-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-197
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
filingDate 2020-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddc16632f5f14a6244cb613c1ba5dd50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da77c155794d974fc8688420baac0dfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f27219b6cb27c9682f725c303b440780
publicationDate 2021-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2021081204-A1
titleOfInvention Disruption of vascular smooth muscle relaxation by carfilzomib may be the primary reason for cfz-induced vascular dysfunction
abstract Provided herein are methods of treating, inhibiting, reducing, or ameliorating cardiovascular adverse events in a patient caused by administration of carfilzomib by administering to the patient at least one of a soluble guanylyl cyclase (sGC) activator, a PDE5 inhibitor, p38 inhibitor, and/or MAPKAPK-2 inhibitor.
priorityDate 2019-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396655
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411370
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398744
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396654
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID172198
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4485
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395471
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395470
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9869929
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400268
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID40461270
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393239
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226420015
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5388962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393691
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396049
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398631
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226420489
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398570
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226427220
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228438845
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6041
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394001
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4782
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398633
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226428649
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5775
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226490661
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID92932
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10351092
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397269
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID443939
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2585
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID187
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395888
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6235
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID110635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399539
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66586609
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226424269
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66586608
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226424268
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13997310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408756
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397425
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3715
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394502
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400247
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8969
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395454

Total number of triples: 83.